Cover Image

Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus

The finding that most grades II and III gliomas harbor isocitrate dehydrogenase (IDH) mutations conveying a relatively favorable and fairly similar prognosis in both tumor grades highlights that these tumors represent a fundamentally different entity from IDH wild-type gliomas exemplified in most gl...

Full description

Saved in:
Bibliographic Details
Main Authors: Schiff, David (Author) , Wick, Wolfgang (Author) , Platten, Michael (Author)
Format: Article (Journal)
Language:English
Published: 08 February 2019
In: Neuro-Oncology
Year: 2019, Volume: 21, Issue: 7, Pages: 837-853
ISSN:1523-5866
DOI:10.1093/neuonc/noz033
Online Access:Verlag, Volltext: https://doi.org/10.1093/neuonc/noz033
Verlag: https://academic.oup.com/neuro-oncology/article/21/7/837/5310249
Get full text
Author Notes:David Schiff, Martin Van den Bent, Michael A. Vogelbaum, Wolfgang Wick, C. Ryan Miller, Martin Taphoorn, Whitney Pope, Paul D. Brown, Michael Platten, Rakesh Jalali, Terri Armstrong and Patrick Y. Wen
Description
Summary:The finding that most grades II and III gliomas harbor isocitrate dehydrogenase (IDH) mutations conveying a relatively favorable and fairly similar prognosis in both tumor grades highlights that these tumors represent a fundamentally different entity from IDH wild-type gliomas exemplified in most glioblastoma. Herein we review the most recent developments in molecular neuropathology leading to reclassification of these tumors based upon IDH and 1p/19q status, as well as the potential roles of methylation profiling and deletional analysis of cyclin-dependent kinase inhibitor 2A and 2B. We discuss the epidemiology, clinical manifestations, benefit of surgical resection, and neuroimaging features of lower-grade gliomas as they relate to molecular subtype, including advanced imaging techniques such as 2-hydroxyglutarate magnetic resonance spectroscopy and amino acid PET scanning. Recent, ongoing, and planned studies of radiation therapy and both cytotoxic and targeted chemotherapies are summarized, including both small molecule and immunotherapy approaches specifically targeting the mutant IDH protein.
Item Description:Gesehen am 21.10.2019
Physical Description:Online Resource
ISSN:1523-5866
DOI:10.1093/neuonc/noz033

Similar Items